Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD and PrecisionCHD tests for eligible members with prior authorization. The coverage expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning.
Cardio Diagnostics said Epi+Gen CHD evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD helps diagnose coronary heart disease and identify its underlying molecular drivers. The company noted that both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, supporting broader adoption of precision cardiovascular medicine across community healthcare networks.
This development is significant because it brings advanced, AI-driven diagnostic tools to a broader patient population, potentially improving early detection and management of coronary heart disease. By integrating these tests into managed care settings, Cardio Diagnostics aims to reduce the burden of cardiovascular disease, which remains a leading cause of death globally. The partnership with Atlas Healthcare Physicians highlights the growing trend of incorporating precision medicine into standard clinical practice, leveraging technology to personalize treatment and improve outcomes.
The Epi+Gen CHD test uses a combination of genetic and epigenetic markers to predict short-term risk, enabling clinicians to intervene earlier with lifestyle modifications or therapies. Meanwhile, PrecisionCHD provides a molecular diagnosis, helping to differentiate coronary heart disease from other conditions and guiding targeted treatments. Both tests are based on Cardio Diagnostics’ proprietary AI-driven Integrated Genetic-Epigenetic Engine, which analyzes complex biological data to deliver actionable insights.
For more information on Cardio Diagnostics and its recent updates, visit the company’s newsroom at https://nnw.fm/CDIO. The full press release is available at https://nnw.fm/EFQen.
